Highlights IceCure Medical Ltd

Equities

ICCM

IL0011224156

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
1.04 ^USD	+1.96%		-8.77%	-2.80%

05-07	Icecure Medical Ltd. Announces That Positive Data from an Independent Study (The "Study") Performed in Japan Was Published in an Article Titled "Percutaneous Ultrasound?Guided Cryoablation for Early?Stage Primary Breast Cancer: A Follow?Up Study in Japan," in the Journal Breast Cancer on April 27, 2024	CI
04-15	IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Icecure Medical Ltd. Announces That Positive Data from an Independent Study (The "Study") Performed in Japan Was Published in an Article Titled "Percutaneous Ultrasound?Guided Cryoablation for Early?Stage Primary Breast Cancer: A Follow?Up Study in Japan," in the Journal Breast Cancer on April 27, 2024	05-07	CI
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer	04-15	MT
IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense	04-15	CI
IceCure Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	04-03	CI
IceCure Medical Seeks FDA Clearance for Cryoablation Technology	04-02	MT
Icecure Submits FDA Regulatory Filing for New Xsense? Cryoablation System with Cryoprobes	04-02	CI
IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study	03-19	CI
IceCure Medical Ltd. Announces Results from an Independent Study	03-04	CI
Icecure Medical Ltd. Announces New Data from A Preliminary, Independent Breast Cancer Study	02-26	CI
Icecure Medical Ltd. Announces U.S. Food and Drug Administration Has Responded Affirmatively to the Company?s Request for Supervisory Review Under 21 Cfr 10.75 Regarding the Fda?S Prior Denial of Icecure?S De Novo Classification Request for Treating Patients with Early-Stage, Low Risk Breast Cancer	01-30	CI
IceCure Medical Regains Nasdaq Compliance	01-12	MT
IceCure Medical Ltd. Announces the Publication of a Study Called "Cryoablation Allows the Ultimate De-Escalation of Surgical Therapy for Select Breast Cancer Patients	12-13	CI
IceCure Medical Ltd. Announces Release of a Study in a Series of Independent Studies of ProSense	11-28	CI
IceCure Medical Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	11-15	CI
IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense in Early-Stage Breast Cancer	11-15	CI
IceCure Medical Ltd. Announces in Parallel with the Growing Adoption of ProSense(R)	11-06	CI
Icecure Medical Ltd. Announces Provides Update on Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's Prosense Cryoablation System	11-06	CI
IceCure Medical Receives Minimum Bid Noncompliance Notice From Nasdaq	11-03	MT
IceCure Medical Says FDA Denies De Novo Classification Request for ProSense System to Treat Breast Cancer; Shares Plunge	23-09-20	MT
IceCure Medical Ltd. Receives FDA Response to De Novo Classification Request for Breast Cancer	23-09-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights IceCure Medical Ltd

Equities

ICCM

IL0011224156

Highlights

Filters